Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2019 Jul 10;28(10):1642–1651. doi: 10.1158/1055-9965.EPI-18-1358

Figure 2.

Figure 2.

Univariate analysis of the combined status for both STAT5 gene locus amplification status and protein expression and progression-free survival with biochemical recurrence (BCR) as the endpoint in prostate cancers of all Gleason GG (A) vs. prostate cancers of Gleason GG 2 and 3 (B) vs. GG 4 and 5 (C). Univariate analysis of the STAT5 gene locus amplification status and progression-free survival in prostate cancers of all Gleason Grade Groups (GG) (D) vs prostate cancers of Gleason GG 2 and 3 (E) vs GG 4 and 5 (F). Univariate analysis of the STAT5 protein status and progression-free survival in prostate cancers of all Gleason Grade Groups (GG) (G) vs. prostate cancers of Gleason GG 2 and 3 (H) vs. GG 4 and 5 (I). Kaplan Meier curves, with global p-values calculated by Mantel-Haenszel tests. The STAT5 protein status detected by immunohistochemistry (IHC) and STAT5 locus amplification by fluorescence in situ hybridization (FISH). Global Mantel-Haenszel log-rank p-values were calculated comparing the difference in survival between all patient groups.